Findings

What do systematic reviews say?

973 questions · 1,024 findings · 106 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 235 · 22.9%GRADE not reported 59 · 5.8%Very low 207 · 20.2%Low 271 · 26.5%Moderate 177 · 17.3%High 75 · 7.3%

Intervention not reported

RVX (high dose, 10 mg to 20 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1389 participants
Low

Intervention not reported

RVX (low dose, 2.5 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1399 participants
Low

Intervention not reported

DAB (low dose, 110 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1962 participants
Low

Intervention not reported

DAB (high dose, 150 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1527 participants
Low

Intervention not reported

RVX (low dose, 2.5 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1399 participants
Low

Intervention not reported

APX vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 4930 participants
Moderate

Intervention not reported

RVX (high dose, 10 mg to 20 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1542 participants
Very low

Intervention not reported

RVX (low dose, 2.5 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1399 participants
Low

Intervention not reported

DAB (low dose, 110 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1962 participants
Low

Intervention not reported

DAB (high dose, 150 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1527 participants
Low

Intervention not reported

APX vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 4930 participants
Low

Intervention not reported

Growth and nutritional status:z‐score for height · children and adults with CF

1 finding from 1 review

Vitamin A and beta (β)‐carotene supplementation for cystic fibrosis 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 24 participants
Low

Intervention not reported

Mortality · children and adults with CF

The review found no eligible studies for this question.

1 finding from 1 review

Vitamin A and beta (β)‐carotene supplementation for cystic fibrosis 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Respiratory outcomes: FEV1 (% predicted): · children and adults with CF

1 finding from 1 review

Vitamin A and beta (β)‐carotene supplementation for cystic fibrosis 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 24 participants
Low

Intervention not reported

Respiratory outcomes: Antibiotic days per patient in past 3 months · children and adults with CF

1 finding from 1 review

Vitamin A and beta (β)‐carotene supplementation for cystic fibrosis 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 24 participants
Low

Intervention not reported

Adverse events · children and adults with CF

1 finding from 1 review

Vitamin A and beta (β)‐carotene supplementation for cystic fibrosis 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 24 participants
Low

Intervention not reported

Annualised relapse rate (ARR) (number of relapses per patient per year) · [People] with [Multiple Sclerosis]

1 finding from 1 review

Vitamin D for the management of multiple sclerosis 2018 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 417 participants
Very low

Intervention not reported

Expanded Disability Status Scale (EDSS) score · [People] with [Multiple Sclerosis]

1 finding from 1 review

Vitamin D for the management of multiple sclerosis 2018 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 221 participants
Very low

Intervention not reported

MRI gadolinium‐enhancing T1 lesions · [People] with [Multiple Sclerosis]

1 finding from 1 review

Vitamin D for the management of multiple sclerosis 2018 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 256 participants
Very low

Intervention not reported

Serious adverse events · [People] with [Multiple Sclerosis]

1 finding from 1 review

Vitamin D for the management of multiple sclerosis 2018 · Cochrane Headline outcomes only
no estimate extracted
8 studies · 621 participants
Low